Hepatology

Results showed metabolic dysfunction was an independent predictor of liver-related events and hepatocellular carcinoma in patients with chronic HCV who achieved SVR.

Study results highlight the role of HCV and alcohol use in the growing global disease burden posed by cirrhosis, which is projected to increase over the next 20 years.

The CRL for the sBLA cites a lack of sufficient data to support the full evaluation of the effectiveness and safety of a 4-dose regimen in this patient population.

At APA 2024, Weinrieb discussed the positive patient outcomes of using a psychiatry-hepatology approach for the treatment of alcohol-associated liver disease.

A novel score based on a combination of cytokeratins and routine laboratory tests provided a more accurate diagnosis of HCC versus serum α-fetoprotein alone.

Glecaprevir/pibrentasvir is an effective treatment for HCV with high rates of SVR, even in patients with cirrhosis undergoing a shorter treatment regimen.

A Veterans Affairs study finds low alpha-1 antitrypsin phenotyping rates, indicating the need for improved healthcare provider education on AATD.

This clinical quiz will test your knowledge of the 2023 American Association for the Study of Liver Diseases/Infectious Diseases Society of America Hepatitis C guideline.

Results suggest chronic hepatitis B virus is globally underassessed and undertreated, especially among women and Asian minorities in the West.

Sofosbuvir/velpatasvir/voxilaprevir rescue therapy was safe and effective, and SVR did not significantly differ based on genotype, cirrhosis, or first-line therapy.

Findings suggest unstable housing may inhibit direct-acting antiviral treatment initiation in PWID with unstable housing compared to those with stable housing.

Maralixibat oral solution improved pruritus and native liver survival in PFIC patients in the MARCH-PFIC trial.

Vitamin D concentration was significant in chronic hepatitis B virus but not hepatitis C virus infection, suggesting its potential impact on immune response.

Results showed 46.45 and 72.74% increases in the global incidences of acute infection and HCV-related cirrhosis, respectively, in reproductive-age women.

Findings suggest metformin and statins have a potective effect against HCC in patients with HCV who fail antiviral therapy.

The April 2024 month in review features HCPLive’s top coverage of resmetirom, other key hepatic pipeline updates, and recent research about hepatitis C virus.

The second segment of a special report stresses the importance of cross-specialty collaboration with hepatology and psychiatry when treating alcohol-related liver disease.

In the first segment of this HCPLive special report, experts discuss the stigma surrounding alcohol use disorder and alcohol-associated liver disease.

Findings highlight an increase in hospitalization among pregnant patients with HCV, further describing age’s impact on mortality, cirrhosis, preterm births, and stillbirths.

Tenofovir disoproxil fumarate was safe and effective for preventing mother-to-child transmission of HBV, but discontinuation was linked to postpartum hepatitis flares.

The modified difference-in-differences analysis found notable increases in DAA use after state Medicaid programs relaxed certain coverage restrictions.

Although overall engagement in the HCV care cascade improved after the introduction of DAAs, vulnerable subgroups still received less testing and treatment.

Results showed poorly controlled HbA1C increased the risk of elevated ALT levels in children and adolescents with type 1 diabetes, suggesting an important link to MASLD.

HBV DNA and HBsAg were not significantly associated with NAFLD in patients with treatment-naïve HBV, but age, BMI, comorbidities, and certain metabolic laboratory parameters were.

Madrigal Pharmaceuticals announced resmetirom is available in the US beginning on April 9, 2024, ushering in a new era of NASH management.